Company registration number 08077110 (England and Wales)
REGENERUS LABORATORIES LIMITED
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MAY 2024
PAGES FOR FILING WITH REGISTRAR
REGENERUS LABORATORIES LIMITED
CONTENTS
Page
Balance sheet
1 - 2
Notes to the financial statements
3 - 8
REGENERUS LABORATORIES LIMITED
BALANCE SHEET
AS AT
31 MAY 2024
31 May 2024
- 1 -
2024
2023
as restated
Notes
£
£
£
£
Fixed assets
Tangible assets
4
45,612
36,413
Current assets
Stocks
9,150
7,500
Debtors
5
1,090,739
286,655
Cash at bank and in hand
538,660
376,034
1,638,549
670,189
Creditors: amounts falling due within one year
6
(1,143,008)
(856,766)
Net current assets/(liabilities)
495,541
(186,577)
Total assets less current liabilities
541,153
(150,164)
Creditors: amounts falling due after more than one year
7
-
0
(50,246)
Provisions for liabilities
(4,554)
-
0
Net assets/(liabilities)
536,599
(200,410)
Capital and reserves
Called up share capital
1,000
1,000
Share premium account
24,750
24,750
Profit and loss reserves
510,849
(226,160)
Total equity
536,599
(200,410)

The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true

For the financial year ended 31 May 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

REGENERUS LABORATORIES LIMITED
BALANCE SHEET (CONTINUED)
AS AT
31 MAY 2024
31 May 2024
- 2 -
The financial statements were approved by the board of directors and authorised for issue on 7 February 2025 and are signed on its behalf by:
Sharon Kay
S Kay
Director
Company registration number 08077110 (England and Wales)
REGENERUS LABORATORIES LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MAY 2024
- 3 -
1
Accounting policies
Company information

Regenerus Laboratories Limited is a private company limited by shares incorporated in England and Wales. The registered office is 78 York Street, London, England, W1H 1DP.

1.1
Reporting period

During the prior period, the company changed it's accounting reference date from 31 March 2023 to a 14 month period ended 31 May 2023.

1.2
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.3
Prior period error

The accounts presented to 31 May 2023 have been restated to include VAT error amendments and related penalties and interest costs which were related to the prior period. The impact to the opening profit and loss reserves for the period to 31 May 2022 was an increase in the loss of £116,555. The impact to the profit and loss for the year ending 31 May 2023 was an increase in the loss of £100,672.

1.4
Going concern

Atruet the time of approving the financial statements, the directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Thus the directors continue to adopt the going concern basis of accounting in preparing the financial statements.

1.5
Turnover

Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.

Revenue from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have passed to the buyer (usually on dispatch of the goods), the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the entity and the costs incurred or to be incurred in respect of the transaction can be measured reliably.

Revenue from contracts for the provision of professional services is recognised by reference to the stage of completion when the stage of completion, costs incurred and costs to complete can be estimated reliably. The stage of completion is calculated by comparing costs incurred, mainly in relation to contractual hourly staff rates and materials, as a proportion of total costs. Where the outcome cannot be estimated reliably, revenue is recognised only to the extent of the expenses recognised that it is probable will be recovered.

1.6
Research and development expenditure

Research expenditure is written off against profits in the year in which it is incurred. Identifiable development expenditure is capitalised to the extent that the technical, commercial and financial feasibility can be demonstrated.

REGENERUS LABORATORIES LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MAY 2024
1
Accounting policies
(Continued)
- 4 -
1.7
Intangible fixed assets - goodwill

Goodwill represents the excess of the cost of acquisition of unincorporated businesses over the fair value of net assets acquired. It is initially recognised as an asset at cost and is subsequently measured at cost less accumulated amortisation and accumulated impairment losses. Goodwill is considered to have a finite useful life and is amortised on a systematic basis over its expected life, which is 5 years.

 

For the purposes of impairment testing, goodwill is allocated to the cash-generating units expected to benefit from the acquisition. Cash-generating units to which goodwill has been allocated are tested for impairment at least annually, or more frequently when there is an indication that the unit may be impaired. If the recoverable amount of the cash-generating unit is less than the carrying amount of the unit, the impairment loss is allocated first to reduce the carrying amount of any goodwill allocated to the unit and then to the other assets of the unit pro-rata on the basis of the carrying amount of each asset in the unit.

1.8
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Leasehold improvements
25% straight line
Plant and equipment
25% reducing balance
Fixtures and fittings
25% reducing balance
Computers
25% reducing balance

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.9
Impairment of fixed assets

At each reporting period end date, the company reviews the carrying amounts of its tangible and intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

1.10
Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition.

 

Stocks held for distribution at no or nominal consideration are measured at the lower of cost and replacement cost, adjusted where applicable for any loss of service potential.

At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.

1.11
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

REGENERUS LABORATORIES LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MAY 2024
1
Accounting policies
(Continued)
- 5 -
1.12
Financial instruments

The Company only enters into basic financial instruments transactions that result in the recognition of financial assets and liabilities like trade debtors and creditors. These are measured at amortised cost and are assessed at the end of each reporting period for objective evidence of impairment. If objective evidence of impairment is found, an impairment loss is recognised in the Statement of comprehensive income.

1.13
Equity instruments

For cash-settled share-based payments, a liability is recognised for the goods and services acquired, measured initially at the fair value of the liability. At the balance sheet date until the liability is settled, and at the date of settlement, the fair value of the liability is remeasured, with any changes in fair value recognised in profit or loss for the year.

1.14
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

 

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

1.15
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

 

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

 

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

REGENERUS LABORATORIES LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MAY 2024
1
Accounting policies
(Continued)
- 6 -
1.16
Retirement benefits

The company operates a defined contribution plan for it's employees. A defined contribution plan is a pension plan under which the company pays fixed contributions into a separate entity. Once the contributions have been paid the company has no further payment obligations. The contributions are recognised as an expense in the Statement of comprehensive income when they fall due. Amounts not paid are shown in accruals as a liability in the Balance sheet. The assets of the plan are held separately from the company in independently administered funds.

1.17
Leases

Rentals payable under operating leases, including any lease incentives received, are charged to profit or loss on a straight line basis over the term of the relevant lease except where another more systematic basis is more representative of the time pattern in which economic benefits from the leases asset are consumed.

2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2024
2023
Number
Number
Total
17
17
3
Intangible fixed assets
Goodwill
£
Cost
At 1 June 2023 and 31 May 2024
500
Amortisation and impairment
At 1 June 2023 and 31 May 2024
500
Carrying amount
At 31 May 2024
-
0
At 31 May 2023
-
0
REGENERUS LABORATORIES LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MAY 2024
- 7 -
4
Tangible fixed assets
Land and buildings
Plant and machinery etc
Total
£
£
£
Cost
At 1 June 2023
19,120
62,522
81,642
Additions
17,264
3,485
20,749
At 31 May 2024
36,384
66,007
102,391
Depreciation and impairment
At 1 June 2023
7,967
37,262
45,229
Depreciation charged in the year
5,140
6,410
11,550
At 31 May 2024
13,107
43,672
56,779
Carrying amount
At 31 May 2024
23,277
22,335
45,612
At 31 May 2023
11,153
25,260
36,413
5
Debtors
2024
2023
Amounts falling due within one year:
£
£
Trade debtors
272,610
103,688
Other debtors
818,129
158,106
1,090,739
261,794
Deferred tax asset
-
0
24,861
1,090,739
286,655
6
Creditors: amounts falling due within one year
2024
2023
£
£
Bank loans
50,246
79,380
Trade creditors
504,635
510,306
Corporation tax
116,579
25,896
Other taxation and social security
193,105
157,835
Other creditors
278,443
83,349
1,143,008
856,766

Investec Capital Solutions Limited hold a fixed and floating charge over all present and future assets and intellectual property owned by the company.

REGENERUS LABORATORIES LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MAY 2024
- 8 -
7
Creditors: amounts falling due after more than one year
2024
2023
£
£
Bank loans and overdrafts
-
0
50,246
8
Operating lease commitments
Lessee

At the reporting end date the company had outstanding commitments for future minimum lease payments under non-cancellable operating leases, as follows:

2024
2023
£
£
86,088
6,650
9
Related party transactions

The company has taken advantage of the exemptions within FRS102 section 1AC.35 (Related Party Disclosure) which allows exemption from the disclosure of related party transactions with other group companies.true

 

During the year, the directors made advances to the company of £1,308 and received credits of £1,107 resulting in a balance due by the company at the year end of £201 (2023 - £Nil). There are no set repayment terms, not is interest charged on the outstanding balance due.

 

10
Parent company

The ultimate controlling party is Omnos Limited. The parent company's registered office and principal place of business is 5 South Charlotte Street, Edinburgh, Scotland, EH2 4AN.

 

2024-05-312023-06-01falsefalsefalse07 February 2025CCH SoftwareCCH Accounts Production 2024.310No description of principal activityS KayJ PriceC Roberts080771102023-06-012024-05-31080771102024-05-31080771102023-05-3108077110core:LandBuildings2024-05-3108077110core:OtherPropertyPlantEquipment2024-05-3108077110core:LandBuildings2023-05-3108077110core:OtherPropertyPlantEquipment2023-05-3108077110core:CurrentFinancialInstrumentscore:WithinOneYear2024-05-3108077110core:CurrentFinancialInstrumentscore:WithinOneYear2023-05-3108077110core:Non-currentFinancialInstrumentscore:AfterOneYear2024-05-3108077110core:Non-currentFinancialInstrumentscore:AfterOneYear2023-05-3108077110core:CurrentFinancialInstruments2024-05-3108077110core:CurrentFinancialInstruments2023-05-3108077110core:ShareCapital2024-05-3108077110core:ShareCapital2023-05-3108077110core:SharePremium2024-05-3108077110core:SharePremium2023-05-3108077110core:RetainedEarningsAccumulatedLosses2024-05-3108077110core:RetainedEarningsAccumulatedLosses2023-05-3108077110bus:Director12023-06-012024-05-3108077110core:Goodwill2023-06-012024-05-3108077110core:LeaseholdImprovements2023-06-012024-05-3108077110core:PlantMachinery2023-06-012024-05-3108077110core:FurnitureFittings2023-06-012024-05-3108077110core:ComputerEquipment2023-06-012024-05-31080771102022-04-012023-05-3108077110core:NetGoodwill2023-05-3108077110core:NetGoodwill2024-05-3108077110core:NetGoodwill2023-05-3108077110core:LandBuildings2023-05-3108077110core:OtherPropertyPlantEquipment2023-05-31080771102023-05-3108077110core:LandBuildings2023-06-012024-05-3108077110core:OtherPropertyPlantEquipment2023-06-012024-05-3108077110core:WithinOneYear2024-05-3108077110core:WithinOneYear2023-05-3108077110core:Non-currentFinancialInstruments2024-05-3108077110core:Non-currentFinancialInstruments2023-05-3108077110bus:PrivateLimitedCompanyLtd2023-06-012024-05-3108077110bus:SmallCompaniesRegimeForAccounts2023-06-012024-05-3108077110bus:FRS1022023-06-012024-05-3108077110bus:AuditExemptWithAccountantsReport2023-06-012024-05-3108077110bus:Director22023-06-012024-05-3108077110bus:Director32023-06-012024-05-3108077110bus:FullAccounts2023-06-012024-05-31xbrli:purexbrli:sharesiso4217:GBP